Novo Nordisk Faces Intensifying Market Pressure as Restructuring Concludes

Novo Nordisk DK0062498333

Novo Nordisk is navigating a pivotal moment. The pharmaceutical giant is nearing the completion of a significant cost-cutting initiative that has eliminated approximately 9,000 positions, even as its chief executive, Mike Doustdar, cautions shareholders about a challenging period ahead. The company’s once-dominant position in the weight-loss medication sector is under threat, with increasing competitive pressure from rivals like Eli Lilly casting a shadow over its upcoming financial results on February 4.